SCHEMBL3568345

SCHEMBL3568345

Cn1c(=O)c(-c2ccc(Cl)cc2Cl)cc2c3cc(C4=NN=C(N)C4=O)ccc3n(C)c21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CNR1 P21554 13/20 0.39
▸ CNR2 P34972 12/20 0.39
▸ GABRA1 P14867 3/20 0.38
▸ ADRA2C P18825 2/20 0.38
▸ SLC6A3 Q01959 2/20 0.38
▸ ADRB3 P13945 1/20 0.38
▸ ADRA2B P18089 1/20 0.38
▸ HTR2A P28223 1/20 0.38
▸ HTR2C P28335 1/20 0.38
▸ OPRD1 P41143 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ EGFR P00533 1/20 0.35
▸ ALOX5 P09917 1/20 0.35
▸ ADORA3 P0DMS8 1/20 0.35
▸ MAPK3 P27361 1/20 0.35
▸ OPRL1 P41146 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3569243 0.89 CNR1 (0.38) CNR1CNR2GABRA1ADRA2CSLC6A3
SCHEMBL3571293 0.87 KDM4E (0.37) CNR1CNR2GABRA1ADRA2CSLC6A3
SCHEMBL3629309 0.81 CNR1 (0.40) CNR1CNR2GABRA1ADRA2CSLC6A3
SCHEMBL1339390 0.81 CNR1 (0.40) CNR1CNR2GABRA1ADRA2CSLC6A3
SCHEMBL1338051 0.80 CNR1 (0.39) CNR1CNR2GABRA1ADRA2CSLC6A3
SCHEMBL3571744 0.80 ALDH1A1 (0.37) GABRA1KDM4EALDH1A1GAAHPGD
SCHEMBL1339432 0.80 CNR1 (0.40) CNR1CNR2GABRA1ADRA2CSLC6A3
SCHEMBL1339276 0.80 MKNK1 (0.43) CNR1CNR2GABRA1ADRA2CSLC6A3
SCHEMBL1339138 0.80 KDM4E (0.48) CNR1CNR2KDM4EALDH1A1GAA
SCHEMBL1339427 0.80 CNR1 (0.38) CNR1CNR2GABRA1ADRA2CSLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7812165-B2 6-substituted pyridoindolone derivatives, production and therapeutic use thereof SANOFI-AVENTIS (FR) 2010-10-12 — — US disclosed
EP-1742947-B1 6-SUBSTITUTED PYRIDOINDOLONE DERIVATIVES PRODUCTION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2008-08-20 — — EP disclosed
US-20070129365-A1 6-Substituted pyridoindolone derivatives, production and therapeutic use thereof SANOFI-AVENTIS (FR) 2007-06-07 — — US disclosed
EP-1742947-A1 6-SUBSTITUTED PYRIDOINDOLONE DERIVATIVES PRODUCTION AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2007-01-17 — — EP disclosed
WO-2005108398-A1 6-SUBSTITUTED PYRIDOINDOLONE DERIVATIVES PRODUCTION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2005-11-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129365-A1 6-Substituted pyridoindolone derivatives, production and therapeutic use thereof PNPO, CYP2D6, DPYD CNR1 387/4885CNR2 448/4885GABRA1 2242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback